Icagen, Inc.Durham, NC, United States (NASDAQ (GM): ICGN)

Tools:

Buy A ReportBecome A Subscriber

Today's Special Offer

Icagen Financial Statements

Icagen Financial Information

Company Type Public
Single Location
Fiscal Year-End December
Investor Relations Company Web Site
Edgar Online logo
This data is provided as per license from EDGAR Online

Icagen Income Statement

  2007 2006 2005
Revenue ($ mil.) 21.1 8.4 8.8
Gross Profit ($ mil.) -- -- --
Operating Income ($ mil.) (12.7) (26.3) (21.7)
Total Net Income ($ mil.) (10.9) (24.8) (20.3)
Diluted EPS (Net Income) (0.29) (1.12) (1.03)
More Icagen financial information

Icagen Quarterly Statements

  Quarter Ending Jun 08 Quarter Ending Mar 08 Quarter Ending Dec 07
Revenue ($ mil.) 3.2 3.0 2.9
Gross Profit ($ mil.) -- -- --
Operating Income ($ mil.) (4.0) (4.0) (4.1)
Total Net Income ($ mil.) (3.7) (3.6) (3.6)
Diluted EPS (Net Income) (0.08) (0.08) (0.09)
More Icagen financial information

Icagen Stock Quote & Chart

10/10/08 14:59:41 EST • NASDAQ • 1.09 • Increased by +0.0500 • Increased by +4.8077 %
Quotes delayed 15 minutes for NASDAQ. 20 minutes for NYSE and AMEX. Market Data provided by Interactive Data. Powered and Implemented by Interactive Data Managed Solutions.
Detailed QuoteInteractive Stock Chart

Icagen Financial Ratios

  Company Industry
Median
Market
Median1
Price/Sales Ratio 3.25 3.54 1.52
Price/Earnings Ratio -- 14.95 15.55
Price/Book Ratio 2.06 2.88 1.47
Price/Cash Flow Ratio -- 12.37 9.50
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.

Detailed Icagen Financial Ratios

Icagen Competitive Intelligence

Abbott Labs Eli Lilly Vertex Pharmaceuticals
Annual Sales ($ mil.) 25,914.2 18,633.5 199.0
Employees 68,000 40,600 1,150
Market Cap ($ mil.) 90,149.7 54,027.9 4,207.3

Competitive Landscape